Prosecution Insights
Last updated: November 20, 2026
Application No. 19/091,995

CLINICAL TRIAL SUPPORT DEVICE, CLINICAL TRIAL SUPPORT METHOD, AND RECORDING MEDIUM

Final Rejection §101§112
Filed
Mar 27, 2025
Priority
May 17, 2024 — JP 2024-080597
Examiner
SHELDEN, BION A
Art Unit
3685
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
NEC Corporation
OA Round
2 (Final)
22%
Grant Probability
At Risk
3-4
OA Rounds
2y 3m
Est. Remaining
42%
With Interview

Examiner Intelligence

Grants only 22% of cases
22%
Career Allowance Rate
73 granted / 331 resolved
-29.9% vs TC avg
Strong +20% interview lift
Without
With
+20.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
34 currently pending
Career history
381
Total Applications
across all art units

Statute-Specific Performance

§101
32.6%
-7.4% vs TC avg
§103
33.1%
-6.9% vs TC avg
§102
6.5%
-33.5% vs TC avg
§112
24.1%
-15.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 331 resolved cases

Office Action

§101 §112
DETAILED ACTION Status of Claims This is a Final Office Action in response to the arguments and/or amendments filed on 16 September 2026. Claim(s) 1, 3-5, 11, and 14-16 is/are amended. Claim(s) 1-16 is/are currently pending and have been examined. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-16 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. Claim 1, which is representative of claims 15 and 16, recites acquire data regarding a treatment of each of a plurality of patients and a selection criterion for selecting a patient to be clinically tested; convert the data regarding the treatment into an embedding vector for each of the plurality of patients; generate, based on a similarity of a feature vector for each patient composed of the embedding vector, a graph indicating a relationship between the plurality of patients in which the plurality of patients are connected by edges connecting similar patients; complement missing data for a data item included in the selection criterion in the data regarding the treatment of a target patient among the plurality of patients by using data of the same data item of one or more other patients connected to the target patient by edges in the graph indicating the relationship between the plurality of patients; calculate a goodness of fit of the data regarding the treatment of the target patient to the selection criterion based on the complemented data; select a patient to be clinically tested based on the goodness of fit; and output information about the selected patient to be clinically tested. The preceding recitation of the claim has had strikethroughs applied to the additional elements beyond the abstract idea to more clearly demonstrate the limitations setting forth the abstract idea. The remaining limitations describe a concept of analyzing patient information by generating a graph and using the graph to impute missing patient data and selecting patients to be clinically tested based on the patient data. This concept describes a process that a clinical investigator should follow to select patients for a clinical trial, similar to the “process that a neurologist should follow when testing a patient for nervous system malfunctions” given in MPEP 2106.04(a)(2)(II)(C) as an example of managing personal behavior in the methods of organizing human activity sub-grouping. As such, these limitation set forth a method of organizing human activity. Therefore the claims are determined to recite an abstract idea. MPEP 2106, reflecting the 2019 PEG, directs examiners at Step 2A Prong Two to consider whether the additional elements of the claims integrate a recited abstract idea into a practical application. Claim 1 recites the additional element of a device comprising at least one memory and at least one processor. Claim 16 recites the additional element of a non-transitory, recording medium. These additional elements are recited at an extremely high level of generality and are interpreted as generic computing devices used to implement the abstract idea. Per MPEP 2106.05(f), implementing an abstract idea on a generic computing device does not integrate an abstract idea into a practical application in Step 2A Prong Two, similar to how the recitation of the computer in the claim in Alice amounted to mere instructions to apply the abstract idea on a generic computer. As such, these additional elements do not integrate the abstract idea into a practical application. There are no further additional elements. Therefore, because the additional elements do not integrate the claims into a practical application the claims are determined to be directed to an abstract idea. At Step 2B of the Mayo/Alice analysis, examiners are to consider whether the additional elements amount to significantly more than the abstract idea. As previously noted, the claims recite additional elements which may be interpreted as generic computing devices used to implement the abstract idea. However, per MPEP 2106.05(f), implementing an abstract idea on a generic computing device does not add significantly more in Step 2B, similar to how the recitation of the computer in the claim in Alice amounted to mere instructions to apply the abstract idea on a generic computer. As such, this additional element does not amount to significantly more. Therefore, the additional elements of the independent claims do not amount to significantly more than the abstract idea. Thus independent claims 1, 15, and 16 are not patent eligible. Dependent claim 2 further recites complement the missing data using non-structural data among the data regarding the treatment. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 2 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 2 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 2 is not patent eligible. Dependent claim 3 further recites complement the generate, for each of the plurality of patients, a complemented data representation vector representing data regarding the treatment of the target patient obtained by complementing the missing data, based on the graph indicating a relationship between the plurality of patients generated based on treatment data items corresponding to the selection criterion among the data regarding the treatment of each of the plurality of patients; and calculate the goodness of fit of the data regarding the treatment of the target patient to the selection criterion based on the feature vector. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 3 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 3 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 3 is not patent eligible. Dependent claim 4 further recites convert the graph indicating the relationship between the plurality of patients and the goodness of fit to the selection criterion for selecting a patient to be clinically tested in each patient into the feature vector of each patient. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 4 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 4 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 4 is not patent eligible. Dependent claim 5 further recites complement the missing data in the data regarding the treatment among the data used for calculating goodness of fit to the selection criterion for selecting a patient to be clinically tested. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 5 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 5 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 5 is not patent eligible. Dependent claim 6 further recites select a patient to be clinically tested from among patients in which the selection criterion is met at a past time point and data regarding a treatment for an implementation period of a clinical trial from a time point at which the selection criterion is met is recorded. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 6 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 6 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 6 is not patent eligible. Dependent claim 7 further recites select the patient to be clinically tested further based on data regarding a treatment of a selected patient as the patient to be clinically tested. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 7 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 7 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 7 is not patent eligible. Dependent claim 8 further recites predict data regarding a treatment at a predetermined time point based on the data regarding the treatment. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 8 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 8 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 8 is not patent eligible. Dependent claim 9 further recites select at least some of patients in a control group based on data of selected patients in a clinical trial group as the patients to be clinically tested. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 9 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 9 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 9 is not patent eligible. Dependent claim 10 further recites select a patient in a clinical trial group based on data of a selected patient in a clinical trial group as the patient to be clinically tested. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 10 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 10 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 10 is not patent eligible. Dependent claim 11 further recites select a patient to be clinically tested from the plurality of patients based on the goodness of fit calculated based on the feature vector. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 11 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 11 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 11 is not patent eligible. Dependent claim 12 further recites complement missing data in the predicted data regarding the treatment. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 12 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 12 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 12 is not patent eligible. Dependent claim 13 further recites predict data regarding a treatment at the predetermined time point for the selected patient to be clinically tested. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 13 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 13 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 13 is not patent eligible. Dependent claim 14 further recites the predetermined time point is a start time point of a clinical trial or a time point during an implementation period of the clinical trial. This limitation further narrows the previously identified method of organizing human activity, but the claim continues to set forth a method of organizing human activity and thus recites a new abstract idea. Dependent claim 14 recites no further additional elements. The previously identified additional element does not integrate the new abstract idea into a practical application for the same reasons indicated above. Therefore dependent claim 14 is determined to be directed to an abstract idea. At Step 2B, the previously identified additional element does not amount to significantly more than the new abstract idea for the same reasons indicated above. Because the dependent claim is directed to an abstract idea without reciting significantly more, dependent claim 14 is not patent eligible. Response to Arguments Applicant’s Argument Regarding 112(b) Rejections of claims 15 and 16: Claims 15 and 16 have been amended in view of the Examiner’s comments. Examiner’s Response: Applicant's amendments filed 16 September 2026 have been fully considered and they resolve the identified issue. The prior rejection under 112(b) is withdrawn. Applicant’s Argument Regarding 103 Rejections of claims 1-16: Independent claims have been amended to recite features that are not taught or suggested by the cited references. Examiner’s Response: Applicant's extensive amendments filed 16 September 2026 have been fully considered. Applicant’s arguments are persuasive. The rejections under 103 are withdrawn. Applicant’s Argument Regarding 101 Rejections of claims 1-16: Without the claimed invention, data items with missing data cannot be used for determination of the goodness of fit, which results in a smaller set of data that is usable. The claimed invention allows a larger set of data to be used for determining the goodness of fit, thereby improving the efficiency of database systems used for the clinical trial support device, as described in paragraph [0021] of the specification. A claim as a whole, including a limitation reflecting the improvement disclosed in the specification, integrates what would otherwise be a judicial exception into a practical application. As explained above, amended claims recite a technical implementation for solving a specific technical problem. In addition, the subject matter of the amended claim recite a specific combination of operations, where such combination is not taught by the cited references. Therefore, Applicant respectfully submits that the additional elements recited in amended claims amount to significantly more than any alleged judicial exception. Examiner’s Response: Applicant's arguments filed 16 September 2026 have been fully considered but they are not persuasive. Examiner notes that the originally filed specification does not use paragraph numbers and thus applicant’s reference to the specification is understood to refer to the pre-grant publication at [0021]. This disclosure does state that “ the clinical trial support system complements missing data among data regarding the treatment necessary for selecting a patient to be clinically tested, thereby expanding the range of patients to be selected, thereby improving the efficiency of selection of the patient to be clinically tested.” However, one of ordinary skill in the art would not understand “expanding the range of patients to be selected” to be any sort of efficiency improvement. While the disclosure repeatedly asserts this efficiency, it does not appear to ever explain it. Per MPEP 2106.05(a), “the disclosure must provide sufficient details such that one of ordinary skill in the art would recognize the claimed invention as providing an improvement.” Here, the unexplained assertion of an efficiency improvement, in a situation where one of ordinary skill in the art would not understand there to be any efficiency improvement, would not cause one of ordinary skill in the art to recognize the invention as providing an improvement. Per MPEP 2106.05(a), “It is important to note, the judicial exception alone cannot provide the improvement.” Here, the asserted improvement appears to be entirely of the abstract idea. Such an improvement does not constitute a technical improvement which would integrate the abstract idea into a practical application or amount to significantly more than the abstract idea. Examiner notes that it is unclear what applicant considers the specific technical problem addressed by the claim. Applicant’s argument appears to be that because the claims recite non-obvious subject matter that they amount to significantly more than the abstract idea. This argument is unambiguously contrary to subject matter eligibility guidance. Per MPEP 2106.05, “the search for an inventive concept should not be confused with a novelty or non-obviousness determination.” Additional Considerations The prior art made of record and not relied upon that is considered pertinent to applicant’s disclosure can be found in the PTO-892 of the prior office action dated 17 June 2026. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bion A Shelden whose telephone number is (571)270-0515. The examiner can normally be reached M-F, 12pm-10pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kambiz Abdi can be reached at (571) 272-6702. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Bion A Shelden/Primary Examiner, Art Unit 3685 2026-11-11
Read full office action

Prosecution Timeline

Mar 27, 2025
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §101, §112
Sep 16, 2026
Response Filed
Nov 13, 2026
Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12776415
MRI-BASED METHOD FOR PREDICTING DEGREE OF ACCUMULATION OF BIOMARKER ASSOCIATED WITH ALZHEIMER'S DISEASE AND COMPANION DIAGNOSIS METHOD USING SAME
2y 2m to grant Granted Oct 27, 2026
Patent 12620475
INTERGRATED MEDICAL MANAGEMENT SYSTEM FOR INTERGRATING AND MANAGING DATA INCLUDING DATA LOCATED ON EXTERNAL SERVERS
3y 0m to grant Granted May 05, 2026
Patent 12591880
Terminal Data Encryption
4y 9m to grant Granted Mar 31, 2026
Patent 12450631
Advanced techniques to improve content presentation experiences for businesses and users
7y 4m to grant Granted Oct 21, 2025
Patent 12412202
APPARATUS AND METHOD FOR PROVIDING CUSTOMIZED SERVICE
2y 1m to grant Granted Sep 09, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
22%
Grant Probability
42%
With Interview (+20.3%)
3y 11m (~2y 3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 331 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month